Trevena (TRVN)
(Delayed Data from NSDQ)
$0.37 USD
-0.04 (-8.96%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $0.37 0.00 (1.09%) 4:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
TRVN 0.37 -0.04(-8.96%)
Will TRVN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TRVN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TRVN
Go Beyond Bargain Hunting; Buy 5 Stocks With Rising P/E
Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates
TRVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aadi Bioscience, Inc. (AADI) Reports Q1 Loss, Tops Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate
Other News for TRVN
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
Buy Rating Affirmed on Trevena as Focus Shifts to Promising Drug Candidate TRV045
Buy Rating Affirmed for Trevena Amid Strategic Focus on Promising TRV045 Development
Recap: Trevena Q4 Earnings